McKesson Inc

Iterion Therapeutics is a clinical-stage biopharmaceutical company based in Houston, TX, dedicated to revolutionizing healthcare through innovative drug discovery. Their lead product, tegavivint, is a first-in-class small molecule inhibitor that targets Transducin Beta-like Protein 1 (TBL1), a key component of the Wnt beta-catenin signaling pathway implicated in various types of cancers. By binding to TBL1 and displacing beta-catenin, tegavivint inhibits oncogenic gene expression, offering a promising approach to treating cancer. Iterion Therapeutics has already demonstrated the safety, pharmacodynamic effects, and clinical activity of tegavivint in a completed Phase 1 clinical trial. They are currently enrolling patients for a company-sponsored clinical trial in hepatocellular carcinoma, a cancer type with a high prevalence of Wnt beta-catenin mutations and significant unmet clinical needs. Additionally, Iterion has established collaborative relationships with leading institutions to further investigate tegavivint's potential in complementary investigator-sponsored trials.Generated from the website

Cardinal Health in Houston, TX is a company that specializes in providing healthcare products and services to various organizations in the medical industry. With a focus on distribution and logistics, Cardinal Health plays a crucial role in ensuring that healthcare facilities have access to the supplies they need to operate efficiently and effectively. Generated from their business information

PETNET Solutions Inc, A Siemens Healthineers Company, is a leading provider of PET radiopharmaceuticals, delivering a wide range of tracers to enhance patient outcomes. With the largest network of cyclotron-equipped radiopharmacies globally, PETNET Solutions ensures reliable and efficient delivery of PET radiopharmaceuticals. Supported by a team of experienced experts, the company offers customized data analytics and educational resources to drive growth in the field of molecular imaging. PETNET Solutions is committed to advancing personalized medicine by investing in its network and increasing patient access to PET biomarkers. Through partnerships with Blue Earth Diagnostics and other industry leaders, the company offers innovative solutions such as the recently approved POSLUMA flotufolastat F 18 injection. With a nationwide presence and a focus on quality and customer care, PETNET Solutions is at the forefront of delivering cutting-edge radiopharmaceuticals to healthcare providers across the United States.Generated from the website